Skye Bioscience (SKYE – Research Report) received a Buy rating and price target from Craig-Hallum analyst Albert Lowe today. The ...

Skye Bioscience (SKYE) announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond Phase 2 clinical trial ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...

Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

At this time, I would like to welcome everyone to the Skye Bioscience Third Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker’s ...

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for ...

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company ...

Available webcasts will be accessible on Skye's website. This press release contains forward-looking statements within the ...